Dysregulated expression of inhibitors of apoptosis (programmed cell death) contributes to cancer by aberrantly extending cell viability, favoring mutations and resistance to therapy. The recent identification of the survivin pathway has suggested that excessive inhibition of apoptosis may constitute a common feature of all human cancers, influencing onset, progression and outcome of malignancy. Survivin was identified as an inhibitor of apoptosis of the LkP gene family, uniquely expressed in mitosis in a cell cycle-regulated manner and localized to the mitotic apparatus. Undetectable in normal adult tissues, survivin becomes the fourth most expressed transcript in cancer, where it correlates with a more aggressive disease and abbreviated life expectancy. Recently, our understanding of the survivin pathway has increased considerably. The crystal structure of survivin has been solved, the critical caspase targeted by survivin has been identified, and the regulation of this pathway by survivin phosphorylation at mitosis has been defined. Importantly, expression of a dominant negative survivin mutant prevented tumor formation and inhibited growth of established tumors, in vivo. The hypothesis underlying the present application is that survivin maintains a critical apoptosis checkpoint at initosis, and that interference with this process is sufficient to cause spontaneous apoptosis of cancer cells. In the first specific aim, we will characterize the structure-function requirements of survivin phosphorylation, its kinetics and regulation, and identify post-phosphorylation events influencing survivin stability. In the second specific aim, we will elucidate the survivin-caspase interaction and its role on caspase activity, processing, mitochondrial homeostasis, and we will reconstitute the survivin pathway in knockout animals deficient in selected apoptosome genes. In the third specific aim, we will use a transgenic approach and adenoviral delivery of a dominant negative survivin mutant to elucidate the contribution of the survivin pathway in tumor formation with respect to oncogene expression, exposure to mutagen or loss of a p53 allele. The overall goal of these studies is to credential the survivin pathway as a potential new therapeutic target in cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA090917-06
Application #
6881562
Study Section
Special Emphasis Panel (ZRG1-MEP (01))
Program Officer
Spalholz, Barbara A
Project Start
2001-04-01
Project End
2006-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
6
Fiscal Year
2005
Total Cost
$296,933
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Biology
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35
Lu, Huimin; Wang, Tao; Li, Jing et al. (2016) ?v?6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Res 76:5163-74
Yu, Jun; Zhang, Yuanyuan; Zhang, Xinbo et al. (2012) Endothelium derived nitric oxide synthase negatively regulates the PDGF-survivin pathway during flow-dependent vascular remodeling. PLoS One 7:e31495
Altieri, Dario C (2010) Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer. Future Oncol 6:487-9
Akech, J; Wixted, J J; Bedard, K et al. (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811-21
Guha, M; Xia, F; Raskett, C M et al. (2010) Caspase 2-mediated tumor suppression involves survivin gene silencing. Oncogene 29:1280-92
van der Deen, Margaretha; Akech, Jacqueline; Wang, Tao et al. (2010) The cancer-related Runx2 protein enhances cell growth and responses to androgen and TGFbeta in prostate cancer cells. J Cell Biochem 109:828-37
Tomaselli, Simona; Meli, Massimiliano; Plescia, Janet et al. (2010) Combined in silico and experimental approach for drug design: the binding mode of peptidic and non-peptidic inhibitors to hsp90 N-terminal domain. Chem Biol Drug Des 76:382-91
Mehrotra, Swarna; Languino, Lucia R; Raskett, Christopher M et al. (2010) IAP regulation of metastasis. Cancer Cell 17:53-64
Altieri, Dario C (2010) Survivin and IAP proteins in cell-death mechanisms. Biochem J 430:199-205

Showing the most recent 10 out of 73 publications